CD274 and neoplasm: When the tumor reached a volume of ≥300 mm3, mice were randomized into the following four treatment groups (n = 5–6/group): control; oral opaganib alone (50 mg/kg/day 5 days/week); anti-PD-L1 antibody alone (200 μg mouse intraperitoneally on Days 1, 3, 5 and 7); and opaganib in combination with anti-PD-L1 antibody.